A little slow aren't they?
Ha I was thinking the same thing--a little LATE to the party, folks!! :)
Pharmacyclics upgraded to Buy from Neutral at Lazard Capital
Lazard Capital upgraded Pharmacyclics with a $141 price target citing the growth potential of the company's cancer drug ibrutinib.
Sentiment: Strong Buy